Bruce A. Mueller, PharmD, is the Interim Dean of the U-M College of Pharmacy. In his 20 years of service to the College, Dean Mueller has found working with students tremendously rewarding, “The best part of my job is working with pharmacy students and helping them achieve their professional goals.” Dean Mueller has a particular interest in incorporating interprofessional education into pharmacy curricula.
Dean Mueller's clinical and laboratory-based research has focused on issues faced by patients with kidney disease for over 25 years. He has published over 100 peer-reviewed papers in the areas of dialysis, pharmacokinetics, continuous renal replacement therapies, and pharmacotherapeutics of kidney disease. His research spans the areas of nephrology, critical care, infectious diseases, pharmacokinetics, and pharmacodynamics. He has trained many current leaders in this area of pharmacy through his work in graduate, residency, and post-doctoral fellowship training programs.
Dean Mueller is a fellow of the American College of Clinical Pharmacy, American Society of Nephrology, and the National Kidney Foundation. He has received numerous teaching awards.
Pharmacokinetics in patients receiving renal replacement therapies, including hemodialysis, peritoneal dialysis, and continuous renal replacement therapies
Extracorporeal treatment of intoxications
Antibiotic pharmacodynamics in patients with kidney disease
Experimental forms of extracorporeal renal replacement therapies
- 2017 St. Catherine's High School Hall of Fame, St. Catherine's High School, Racine, Wis
- 2015 American College of Clinical Pharmacy's Critical Care PRN Research Award, ACCP
- 2015 Michigan Institute for Clinical & Health Research Distinguished Clinical and Translational Research Mentor Award, University of Michigan
- 2015 University of Michigan Provost’s Teaching Innovation Prize (Faculty Team Lead - Burgunda Sweet), University of Michigan
- 2015 65th Annual University of Wisconsin Kremers Lecturer, University of Wisconsin
- 2011 Fellow of the National Kidney Foundation, National Kidney Foundation
- 2009 Fellow in the American Society of Nephrology, American Society of Nephrology
- 2000 University Faculty Scholar, Purdue University, Purdue University
Crass RL, Rodvold KA, Mueller BA, Pai MP. Renal Dosing of Antibiotics: Are We Jumping the Gun? Clin Infect Dis 2019;68:1596-1602.
Jang SM, Pai MP, Shaw AR, Mueller BA. Antibiotic exposure profiles in trials comparing intensity of continuous renal replacement therapy. Crit Care Med 2019 DOI: 10.1097/CCM.0000000000003955
Scoville BA, Segal JH, Salama NN, Heung M, Bleske B, Eyler RF, Mueller BA. Single Dose Oral Ranolazine Pharmacokinetics in Patients Receiving Maintenance Hemodialysis. Renal Failure 2019;41:118-125
Jang SM, Gharibian KN, Lewis, SJ, Fissell WH, Tolwani AT, Mueller BA. A Monte Carlo Simulation Approach for Beta-lactam Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy. J Clin Pharmacol 2018: 10.1002/jcph.1137
Shaw AR, Chaijamorn W, Clark JS, Mueller BA. Preparation times and costs for various solutions used for continuous renal replacement. Am J Health-System Pharm 2018 2018, 75 (11) 808-815.
Scoville BA, Vulaj V, Mueller BA, Annich GM, Wagner DS. Acetaminophen Clearance During Ex Vivo Continuous Renal Replacement Therapies. J Artif Organs. J Artif Organs (2018) 21: 215.
Sweet BV, Madeo A, Fitzgerald M, House J, Pardee M, Zebrack B, Sweier D, Hornyak J, Arslanian-Engoren C, Mattison D, Dubin L,Stojan J, Mueller BA. Moving from individual roles to functional teams: A semester-long course in case-based decision making. J Interprof Educ Practice 2017;7:11-16.
Lewis SJ, Chaijamorn W, Shaw A, Mueller BA. In silico Trials Using Monte Carlo Simulation to Evaluate Ciprofloxacin and Levofloxacin Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy. Ren Replace Ther 2016, 2:45.
Eyler RF, Vilay AM, Nader AM, Heung M, Pleva M, Sowinski KM, DePestel DD, Sörgel F, Kinzig M, Mueller BA. Pharmacokinetics of ertapenem in critically ill patients receiving continuous venovenous hemodialysis or hemodiafiltration. Antimicrobial Agents and Chemotherapy. 2014;58(3):1320-1326.
Rachel F. Eyler; A. Mary Vilay; Ahmed M. Nader; Michael Heung; Melissa Pleva; Kevin M. Sowinski; Daryl D. DePestel; Fritz Sörgel; Martina Kinzig; Bruce A. Mueller Pharmacokinetics of ertapenem in critically ill patients receiving continuous venovenous hemodialysis or hemodiafiltration Antimicrobial Agents and Chemotherapy. 2014;58(3):1320-1326.